Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,732 Million (Large Cap)
28.00
NA
2.31%
-0.41
10.81%
2.86
Revenue and Profits:
Net Sales:
893 Million
(Quarterly Results - Dec 2025)
Net Profit:
223 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.12%
0%
-2.12%
6 Months
-13.16%
0%
-13.16%
1 Year
5.24%
0%
5.24%
2 Years
5.62%
0%
5.62%
3 Years
-9.62%
0%
-9.62%
4 Years
-5.81%
0%
-5.81%
5 Years
-0.51%
0%
-0.51%
Tibet Cheezheng Tibetan Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.82%
EBIT Growth (5y)
10.36%
EBIT to Interest (avg)
9.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.39
Tax Ratio
10.20%
Dividend Payout Ratio
34.61%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.58%
ROE (avg)
15.58%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
3.69
EV to EBIT
22.04
EV to EBITDA
17.77
EV to Capital Employed
5.29
EV to Sales
5.44
PEG Ratio
NA
Dividend Yield
2.91%
ROCE (Latest)
23.99%
ROE (Latest)
13.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
893.10
866.20
3.11%
Operating Profit (PBDIT) excl Other Income
271.10
220.70
22.84%
Interest
0.00
12.50
-100.00%
Exceptional Items
0.00
36.90
-100.00%
Consolidate Net Profit
222.70
187.00
19.09%
Operating Profit Margin (Excl OI)
303.50%
213.30%
9.02%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 3.11% vs 8.42% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 19.09% vs -6.31% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,416.00
2,311.20
4.53%
Operating Profit (PBDIT) excl Other Income
763.00
675.50
12.95%
Interest
0.00
60.40
-100.00%
Exceptional Items
0.00
105.10
-100.00%
Consolidate Net Profit
646.20
581.40
11.15%
Operating Profit Margin (Excl OI)
315.80%
231.50%
8.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.53% vs 14.49% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 11.15% vs 0.38% in Dec 2024
About Tibet Cheezheng Tibetan Medicine Co., Ltd. 
Tibet Cheezheng Tibetan Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






